The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Identification of genetic markers associated with ibrutinib-related cardiovascular toxicity
Nilanjan Ghosh MD, PhD, Levine Cancer Institute, Charlotte, NC, discusses the identification of polymorphisms in genes of the Bruton’s Tyrosine Kinase (BTK) signaling pathway associated with ibrutinib-related cardiovascular side effects (CVSEs) observed in patients with chronic lymphocytic leukemia (CLL). In patients with CLL treated with ibrutinib monotherapy, five single nucleotide polymorphisms (SNPs) were significantly associated with CVSEs: GATA4, SGK1, KCNQ1, NPPA and SCN5A. A genetic risk score indicated increased risk of CVSEs in patients with at least two SNPs. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
